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Abstract 
Epigenetic deregulation is a common feature in the pathogenesis of Epstein–Barr Virus (EBV)-related lymphomas and 
carcinomas. Previous studies have demonstrated a strong association between EBV latency in B-cells and epigenetic 
silencing of the tumor suppressor gene BIM. This study aimed to the construction and functional analysis of the BIM 
interactome in order to identify novel host genes that may be targeted by EBV. Fifty-nine unique interactors were 
found to compose the BIM gene network. Ontological analysis at the pathway level highlighted infectious diseases 
along with neuropathologies. These results underline the possible interplay between the BIM interactome and EBV-
associated disorders.
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It is well established that the epigenetic interplay 
between Epstein–Barr Virus (EBV) and the host con-
tributes to the pathogenesis of EBV-related diseases [1, 
2]. Previous studies have revealed that EBV latency in 
B-cells leads to the epigenetic silencing of the BCL2-Like 
11 apoptosis facilitator (BIM) [3, 4]. This study presents 
a bioinformatic analysis towards the identification and 
functional prediction of BIM interacting partners so as 
to indicate new, potential host targets of EBV. The gene 
network of BIM was constructed by interrogating the fol-
lowing three databases: Biogrid (http://thebiogrid.org), 
String (http://string-db.org) and GeneMania (http://
www.genemania.org). The Biogrid database is a reposi-
tory of genetic and protein–protein interactions that are 
curated from the primary biomedical literature for all 
major model organism species [5]. String is a database 
of known and predicted protein interactions including 
both direct (physical), and indirect (functional) associa-
tions [6]. GeneMania is a prediction server that generates 
hypotheses about gene function, analyzes gene lists and 
prioritizes genes for functional assays [7]. Subsequently, 
the Human Gene Compendium-GeneCards (http://www.
genecards.org) was used in order to assess the descrip-
tion of the retrieved genes. GeneCards is an integrated 
database of human genes that provides concise genomic 
related information, on all known and predicted human 
genes [8]. BIM interactors that were found in all three 
databases were then entered as a list in the GeneCodis3 
database (http://genecodis.cnb.csic.es/) for functional 
enrichment analysis of Gene Ontology (GO) annota-
tions relative to cellular pathways. GeneCodis is a tool 
for modular and singular enrichment analysis oriented to 
integrate information from different sources [9]. Annota-
tions selected were KEGG and PANTHER pathways. The 
p values were obtained through Hypergeometric analysis 
corrected by the False Discovery Ratio (FDR) method. 
The option of high confidence/no more than ten interac-
tors was selected in the String database so as to increase 
the level of certainty.
Fifty-nine unique BIM interactors were identified. 
Seven of these interactors (MCL1: myeloid cell leukemia 
1; BCL2L1: BCL2-like 1; BCL2: B cell CLL/lymphoma 
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2; DYNLL1: dynein, light chain, LC8-type 1; BCL2L2: 
BCL2-like 2; MAPK8: mitogen-activated protein kinase 
8; BAX: BCL2-associated X protein) appeared in all three 
databases and were further subjected to functional anal-
ysis as the level of confidence for the common genes is 
much more significant. The modular enrichment analysis 
identified: (1) pathways related to cancer including apop-
tosis, (2) pathways related to Amyotrophic Lateral Scle-
rosis (ALS), and (3) pathways related to other infectious 
diseases like tuberculosis and toxoplasmosis (Table  1). 
The singular enrichment analysis of KEGG and PAN-
THER pathways highlighted: (1) pathways involved in 
cancer as JAK-STAT and Wnt signalling pathways, (2) 
pathways related to neurodegenerative disorders [like 
Huntington’s disease (HD) Parkinson disease (PD), Alz-
heimer disease (AD) and ALS], (3) pathways involved in 
infectious diseases like epithelial cell signalling in Escher-
ichia coli infection, Chagas disease, Hepatitis C and prion 
diseases (results not shown).
EBV is a known oncogenic virus associated with 1  % 
of cancers worldwide [10]. The interactions of EBV with 
members of the Bcl-2 family like BAX, BCL2, BCL2L1, 
BCL2L2 and MCL1 in human tumor cells, have been 
extensively reviewed in Fu et  al. [11]. Thus, the predic-
tion that the BIM interactome is involved in cancer 
pathways was not surprising. The main finding of this 
study is the indication that several BIM interactors par-
ticipate in pathways related to neurodegenerative disor-
ders. In such diseases, like AD, PD, ALS and—to a less 
extent—HD, many studies have highlighted the impor-
tance of the immune system and the involvement of 
neuroinflammation [12]. It has been suggested that the 
adaptive immune response to EBV represents the key ini-
tiating event in PD [13]. Recently, a study has reported on 
a high level of octapeptide matching between 7 viruses 
(including EBV), and human brain antigens that, when 
altered, have been specifically associated with neuro-
pathologies such as ALS, HD and PD [14]. Another 
important finding arising from the ontological analysis 
is the prediction that the BIM interactome participates 
in pathways associated with other infectious agents. 
The cooperative contribution of HIV, malaria and EBV 
in lymphomagenesis has long been established while 
the possibility of synergy between EBV and Helicobac-
ter pylori in the pathogenesis of gastric carcinomas has 
recently begun to unfold [15]. Any possible association of 
EBV with other infectious diseases revealed by the func-
tional analysis remains to be studied.
Cumulatively, by using contemporary bioinformatic 
tools this study has demonstrated that the BIM regula-
tory network consists of 59 unique genes that could be 
targeted by EBV. Furthermore, it has predicted that sev-
eral BIM interactors have a central role in pathways asso-
ciated with neurodegenerative disorders and infectious 
diseases. The BIM interactome warrants further study, 
in terms of clinical research, with respect to its interplay 
with EBV.
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Table 1 Results of the modular enrichment analysis in the GeneCodis3 database
p values have been obtained through Hypergeometric analysis corrected by the False Discovery Ratio (FDR) method. Annotations selected were KEGG and PANTHER 
pathways
NGR number of annotated genes in the reference list, TNGR total number of genes in the reference list, NG number of annotated genes in the input list, TNG total 
number of genes in the input list, Hyp Hypergeometric p value, Hyp* corrected hypergeometric p value
Genes NGR TNGR NG TNG Hyp Hyp* Annotations
6 107 34,208 6 7 5.67 × 10−15 2.84 × 10−14 Panther pathways P00006: Apoptosis signalling pathway
3 5 34,208 3 7 5.25 × 10−11 8.74 × 10−11 KEGG 04141: Protein processing in endoplasmic reticulum
KEGG 04722: Neurotrophin signalling pathway
KEGG 05200: Pathways in cancer
KEGG 05152: Tuberculosis
Panther pathways P00006: Apoptosis signalling pathway
KEGG 05210: Colorectal cancer
4 37 34,208 4 7 4.04 × 10−11 1.01 × 10−10 KEGG 05200: Pathways in cancer
Panther pathways P00006: Apoptosis signalling pathway
3 9 34,208 3 7 4.40 × 10−10 5.51 × 10−10 KEGG 05200: Pathways in cancer
KEGG 05014: Amyotrophic Lateral Sclerosis (ALS)
Panther pathways P00006: Apoptosis signalling pathway
KEGG 04210: Apoptosis
3 26 34,208 3 7 1.36 × 10−08 1.36 × 10−08 KEGG 05200: Pathways in cancer
KEGG 05145: Toxoplasmosis
Panther pathways P00006: Apoptosis signalling pathway
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